News | October 22, 2006

Discrepancy Found in Use of Standard Tests to Diagnose Lung vs. Cardiac Disease

Chronic obstructive pulmonary disease (COPD) and congestive heart failure (CHF) are two of the most common medical reasons for hospitalization among middle-aged and older patients. Both have accepted standards for diagnosis and management, supported by large bodies of scientific evidence and international practice guidelines; yet a new study from Boston’s Caritas St Elizabeth’s Medical Center, published in the October issue of Respiratory Care, shows that the use of the primary confirmatory tests—recommended both for diagnosis and assessment of severity—differs substantially in the two diseases.     

According to guidelines such as those of the Global Initiative for Obstructive Lung Disease (www.goldcopd.com), diagnosing COPD and choosing appropriate therapy based on disease severity relies on spirometry, a simple test in which lung capacity and how fast air can be expelled from the lungs are measured noninvasively in a doctor’s office or laboratory. 

The new study, by Mahendra Demarla and colleagues, shows that only about one-third of patients admitted to the hospital with the diagnosis of “COPD” during a recent 6-month period had had spirometry performed either in the hospital or during the preceding 8 years. This means that the majority of patients who required hospitalization for this common and life-threatening condition had not undergone the specific test required to confirm that this diagnosis was correct. 

Further, the investigators found that, of the patients who had undergone spirometry, in 10% of instances the findings were normal, indicating that the diagnosis of COPD was incorrect, and in another 19% it revealed a different functional pattern suggesting the presence of some other lung disease.

Related Content

News | Image Guided Radiation Therapy (IGRT) | July 31, 2017
Elekta’s magnetic resonance radiation therapy (MR/RT) system will be the subject of 21 abstracts at the 59th American...
News | Image Guided Radiation Therapy (IGRT) | July 13, 2017
Elekta and Sunnybrook Health Sciences Centre have initiated installation of Elekta’s MR-linac, an investigational...
First New York Metropolitan Hospital Treats Cancer Patients With Accuray Radixact System
News | Image Guided Radiation Therapy (IGRT) | July 03, 2017
Accuray Inc. and Montefiore Einstein Center for Cancer Care (MECCC), part of the Montefiore Health System (MHS),...
IUCT Oncopole Installs First Radixact Radiotherapy System in France
News | Intensity Modulated Radiation Therapy (IMRT) | June 20, 2017
Accuray Inc. announced that the University Cancer Institute of Toulouse Oncopole (IUCT Oncopole) in Toulouse, France,...
Henry Ford Cancer Institute First in World to Install Viewray MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | June 19, 2017
The Henry Ford Cancer Institute is the first in Michigan – and first in the world – to offer patients advanced...
News | Image Guided Radiation Therapy (IGRT) | May 24, 2017
The University Medical Centre (UMC) Utrecht in the Netherlands recently treated the first patient as part of a clinical...
Mevion and medPhoton Bring Advanced Cone Beam CT Imaging to Proton Therapy
News | Proton Therapy | May 04, 2017
Mevion Medical Systems announced a strategic agreement with medPhoton GmbH to integrate ImagingRing, an innovative cone...
ViewRay, MRIdian Linac system, FDA 510k approval, MRI-guided radiation therapy
Technology | Image Guided Radiation Therapy (IGRT) | February 27, 2017
February 27, 2017 — ViewRay Inc. announced that the company received 510(k) clearance from the U.S.
Overlay Init